Home › Mutual Funds › Nippon India Mutual Fund › Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Add To Compare

previously known as Nippon India Pharma Dir DR until

147.589 (-0.537%)
NAV on April 19, 2024
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 7,125 cr
Turnover Ratio 18.67%
Expense Ratio 0.92%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: 0.56%
  • 1Y: 48.55%
  • 3M: 2.54%
  • 3Y: 17.78%
  • 6M: 19.44%
  • 5Y: 25.32%
Min Investment 5,000
Buy Now Start SIP
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since about 19 years) Kinjal Desai (Since almost 6 years)
ISIN INF204K01I43
Fund Family Nippon India
P/E Ratio 40.73
P/B Ratio 6.18
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 3.41
Beta 0.93
R-Squared 96.04
Info Ratio 0.98
Tracking Err 3.22
Sortino 1.900
Sharpe 1.036
Std Dev 15.327
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Dividends that would otherwise be paid out to investors are instead used to purchase more units in the fund. Not as tax efficient as Growth.

View Factsheet
-
Best Arbitrage Fund Funds
NAME LATEST
NAV		 RETURNS
1y     		FUND
ASSETS		 Expense
RATIO		 RISK
Quant
Quant Healthcare Fund Direct Growth
13.633 — 265 cr 0.73% -
Best Sector Healthcare Funds
NAME LATEST
NAV		 RETURNS
1y     		FUND
ASSETS		 Expense
RATIO		 RISK
Icici
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
32.100 57.12% 3,772 cr 1.04% -
Sbi
SBI Healthcare Opportunities Fund Direct Growth
384.515 53.03% 2,626 cr 0.95% -
Tata
Tata India Pharma & Healthcare Fund Direct Growth
28.023 51.25% 879 cr 0.83% -
Idbi mutual fund
LIC MF Healthcare Fund Direct Growth
25.344 44.00% 62 cr 1.21% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon India Fund